Feb
2003

US NAT yield: where are we after 2 years?

Stramer SL
Transfus Clin Biol 2003;10(1):10-18.
NATA Rating :
Review by :
NATA Review
Discussion of very recent literature, calculation of current risk of transfusion transmitted viral infections after introduction of NAT-HCV and NAT-HIV. Determination of cost/benefit of introduction of NAT. Conclusive statement that p24 antigen testing should be omitted after introducztion of
NAT.

– Volker Kretschmer